# Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

> **NCT01701479** · PHASE1,PHASE2 · UNKNOWN · sponsor: **St. Anna Kinderkrebsforschung** · enrollment: 288 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** ch14.18/CHO
- **DRUG:** Aldesleukin
- **DRUG:** Isotretinoin

## Key facts

- **NCT ID:** NCT01701479
- **Lead sponsor:** St. Anna Kinderkrebsforschung
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 288 (ESTIMATED)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701479, "Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01701479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*